Evidence map›Paper›PMID 33795020›Full record

ArticleChinese neurosurgical journal2021

Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study.

Yuchen Wu, Xuefei Sun, Xueyan Bai, Jun Qian, Hong Zhu, Qu Cui, Ruixian Xing, Yuedan Chen, Qing Liu, Wenyuan Lai and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese neurosurgical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yuchen WuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuefei SunDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xueyan BaiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jun QianDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hong ZhuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Qu CuiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ruixian XingDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuedan ChenDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Qing LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wenyuan LaiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Junhong LiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yaming WangDepartment of Neurosurgery, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.
Shengjun SunNeuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Nan JiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuanbo LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. yuanbol@ccmu.edu.cn.ORCID http://orcid.org/0000-0003-1703-6774
Capital Medical University · CN

Funding

Capital's Funds for Health Improvement and Research 2020-2-2049
6 · The paper itself

Abstract

backgroundSecondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined.

methodsWe conducted a retrospective study to assess the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients.

resultsNineteen patients with newly diagnosed CNS lesions were selected, with a median age of 58 (range 20 to 72) years. Out of 19 patients, 11 (57.9%) achieved complete remission (CR) and 2 (10.5%) achieved partial remission (PR); the overall response rate was 68.4%. The median progression-free survival after CNS involvement was 28.0 months (95% confidence interval 11.0-44.9), and the median overall survival after CNS involvement was 34.5 months. Treatment-related death occurred in one patient (5.3%).

conclusionsThese single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL, further investigation is warranted.

Indexed as

B cell lymphomaCentral nervous systemChemotherapyR-MIADDSCNSL

Identifiers

PMID33795020
PMCPMC8017776
OpenAlexW3150512696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.